NT5E and neoplasm: The A2BR antagonists PBF-1129 and TT-702 as well as the dual A2AR/A2BR antagonists Etrumadenant (AB928) and M1069 were developed to target the myeloid, stromal and potential tumor cell-mediated immunosuppression for additive/synergistic effects of dual CD73-AR axes blockade.